Targeting multiple signaling steps to achieve synergy
Ended Cooperative Agreement Awarded Last action
- Award ID
- R01CA163015
- Recipient
-
Optimum Therapeutics, LLC UEI CAAGN783MMF1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,915,391
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- Carlsbad, CA 92008, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $390,100 | |
| Amendment | $1 | |
| Amendment | -$1 | |
| Amendment | $390,100 | |
| Amendment | $378,396 | |
| Amendment | $1 | |
| Amendment | $191,149 | |
| Amendment | $175,545 | |
| Amendment | -$316,438 | |
| Amendment | $390,100 | |
| Original award | $316,438 |
Show all 13
Quick answers
Who received award R01CA163015?
R01CA163015 was awarded to Optimum Therapeutics, LLC by National Cancer Institute (National Institutes of Health) on April 1, 2012.
How much is award R01CA163015 worth?
$1,915,391 has been obligated on R01CA163015.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award